Polaris Group announced the submission to MFDS of POLARIS2020-001 Phase 2 Trial of ADI-PEG 20. Phase 2 trial is a global, multi-center, randomized, double-blind, placebo controlled study to enroll 100 patients. The primary endpoint is Overall Survival and secondary endpoints are PFS, DOR and Response Rate will be examined based on investigators and assessments.

Polaris Group will keep patient enrollment on schedule. New drug name or code: ADI-PEG 20. Purpose: Treatment for cancer.

Planned development stages: Phase 2. Current development stage: File application/approved/disapproved/Each of clinical trials (include interim analysis): File application; Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks and the associated measures the Company may occur: NA; After obtaining official approval or the results (include interim analysis) of statistically significant sense, the future strategy: NA; Accumulated investment expenditure incurred: No disclosure due to confidentiality; Upcoming development plan: Start Phase 2 patient enrollment.